Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma

PURPOSE: Surgery is the primary therapy for localized chondrosarcoma; for locally advanced and/or metastatic disease, no known effective systemic therapy exists. Mutations in the isocitrate dehydrogenase 1/2 (IDH1/2) enzymes occur in up to 65% of chondrosarcomas, resulting in accumulation of the onc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Tap, William D., Villalobos, Victor M., Cote, Gregory M., Burris, Howard, Janku, Filip, Mir, Olivier, Beeram, Murali, Wagner, Andrew J., Jiang, Liewen, Wu, Bin, Choe, Sung, Yen, Katharine, Gliser, Camelia, Fan, Bin, Agresta, Sam, Pandya, Shuchi S., Trent, Jonathan C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7238491/
https://ncbi.nlm.nih.gov/pubmed/32208957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02492
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados